GEHCV GE HEALTHCARE TECHNOLOGIES INC

University of California San Francisco and GE HealthCare Launch a Joint Research Program to Drive Innovations in Imaging, Brain Health and Precision Oncology

University of California, San Francisco (UCSF) Department of Radiology & Biomedical Imaging and GE HealthCare today announced the launch of a Care Innovation Hub, a joint research collaboration that aims to address meaningful clinical challenges in three key areas: accessibility to advanced medical imaging, non-invasive diagnosis and management of neurological and neurodegenerative disease, and precision oncology. The Care Innovation Hub leverages the strengths of academia and industry to create, evaluate and translate novel technology into a clinical setting with the goals of advancing diagnosis and treatment of disease, improving hospital operations and driving more equitable access to care.

The Care Innovation Hub builds on a decades-long history between UCSF and GE HealthCare, bringing research focus areas under one framework. It integrates the research and clinical expertise of UCSF in critical care areas such as brain health, neurodegenerative disease and oncology, with GE HealthCare’s deep knowledge in research and product development.

“Our collaboration with GE HealthCare brings a practical focus on addressing well-defined clinical objectives,” said Sharmila Majumdar, PhD, Research Vice Chair in the UCSF Department of Radiology & Biomedical Imaging. “Together, we’re accelerating innovation in ways that will improve access to care and outcomes across healthcare settings.”

The Care Innovation Hub centers on three focus areas designed to address impactful clinical goals and answer critical questions in the field of medical imaging and treatment:

  • Building an imaging service line of the future
  • Advancing solutions for neurodegenerative disease
  • Driving Accessible Precision Oncology

“We’re honored to collaborate with UCSF on this important work, which has the potential to significantly improve patient outcomes and address life-threatening diseases like Alzheimer’s disease and prostate cancer worldwide,” said Erin Angel, PhD, GE HealthCare Global Vice President, Research and Scientific Affairs. “By combining our strengths, we’re taking steps toward solutions that meet real clinical needs. Together, we’re building something we hope will make a meaningful difference for patients and the future of healthcare.”

Building an imaging service line of the future

UCSF and GE HealthCare aim to dramatically improve medical imaging services by developing more automated imaging methods, such as patient-specific magnetic resonance imaging (MRI) techniques that could adapt to patient needs in real time. This aims to increase efficiency and accessibility to create more consistent, high quality, and personalized care. Projects within this focus area concentrate on advancing quantitative imaging for cardiac and musculoskeletal disease and developing methods to enable high-quality remote scanning.

This focus area aims to answer the question: Can we build a fully automated imaging service line that delivers exceptional care, minimizes inefficiencies and adapts to patients in real time?

Advancing solutions for brain health and neurodegenerative disease

UCSF and GE HealthCare aim to expand understanding of brain functions using advanced imaging. The team aims to explore the links between white matter injury, vascular disease, and Alzheimer’s disease, and identify ways to predict treatment efficacy for brain health interventions.

This focus area aims to answer the question: Can we leverage advanced imaging to evaluate aging and biomarkers to better understand neurodegenerative disease, including Alzheimer’s disease?

Driving Accessible Precision Oncology

UCSF and GE HealthCare hope to develop quantitative imaging methods to monitor patient response to radiopharmaceutical therapies (RPTs) and create protocols to expand access to these emerging treatments. The team aims to standardize processes for new approaches, such as visualization of alpha-emitting radiopharmaceuticals. Through this work, the team aims to establish quantitative methods to assess how a patient is responding to treatment, and build, evaluate, and translate novel diagnostic innovations to patient care.

This focus area aims to answer the question: Can we create new methods to assess how a patient is responding to RPT and expand access to theranostics to clinicians and patients in their own communities?

The collaboration research activities will take place at University of California, San Francisco facilities in the San Francisco Bay Area, California.

About University of California San Francisco Department of Radiology & Biomedical Imaging

The University of California, San Francisco is the leading university exclusively focused on health. Through advanced biomedical research, graduate-level education in the life sciences and health professions, and excellence in care delivery, UCSF spearheads revolutions in health worldwide.

The Department of Radiology and Biomedical Imaging at the University of California, San Francisco, is a leading health sciences center focused on serving patients, conducting research, and training the next generation of radiologists. We are proud to have some of the foremost names in diagnostic, therapeutic, and interventional radiology developing promising new approaches to identify and treat disease.

Visit our main and department websites for more information: and .

About GE HealthCare Technologies Inc.

GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, dedicated to providing integrated solutions, services, and data analytics to make hospitals more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected, and compassionate care, while simplifying the patient’s journey across the care pathway. Together our Imaging, Advanced Visualization Solutions, Patient Care Solutions, and Pharmaceutical Diagnostics businesses help improve patient care from diagnosis, to therapy, to monitoring. We are a $19.6 billion business with approximately 51,000 colleagues working to create a world where healthcare has no limits.

Follow us on , , , , and for the latest news, or visit our website for more information.

EN
15/01/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on GE HEALTHCARE TECHNOLOGIES INC

 PRESS RELEASE

GE HealthCare launches AI-driven, patient-friendly Invenia ABUS Premiu...

CHICAGO--(BUSINESS WIRE)-- GE HealthCare (Nasdaq: GEHC) announced the launch of Invenia™ Automated Breast Ultrasound (ABUS) Premium, the latest 3D ultrasound offering advanced artificial intelligence (AI) and innovative features to drive faster*, reproducible supplemental screening and streamline exam readings on patients with dense breasts. Approximately 71% of cancers occur in dense breasts.1 According to studies across the U.S. and Europe, 40% of women2 and 70% of Asian women3 have dense breast tissue, making them four to six times more likely to receive a breast cancer diagnosis.4 Early d...

 PRESS RELEASE

GE HealthCare and NVIDIA reimagine diagnostic imaging with autonomous ...

SAN JOSE, Calif.--(BUSINESS WIRE)-- GE HealthCare (Nasdaq: GEHC) today announced a collaboration with NVIDIA at GTC 2025, expanding the existing relationship between the two companies to focus on pioneering innovation in autonomous imaging, beginning with autonomous X-ray technologies and autonomous applications within ultrasound. GE HealthCare has been at the forefront of medical technology innovation with a series of “firsts” that date back more than a century, starting with the invention of its X-ray tube, followed by several others including the first handheld ultrasound, first 3D obstetr...

 PRESS RELEASE

GE HealthCare expands invasive cardiology solutions portfolio with Alt...

CHICAGO--(BUSINESS WIRE)-- GE HealthCare (Nasdaq: GEHC) today announced the launch of the AltiX AI.i edition of Mac-Lab™, CardioLab™ and ComboLab™. The AltiX AI.i editions are designed to improve the user experience, elevating workflow in the cardiac catheterization (cath) lab and supporting even the most complex electrophysiology (EP) procedures. These latest editions offer new features that can streamline workflow and enhance interoperability, while upholding strong cybersecurity standards. Cardiovascular disease (CVD) has nearly doubled over the past three decades, affecting more than 500 ...

 PRESS RELEASE

GE HealthCare Advances Its Cloud Strategy by Unveiling the Genesis Por...

LAS VEGAS--(BUSINESS WIRE)-- GE HealthCare (Nasdaq: GEHC) today announced its new Genesis solutions, a portfolio of cloud enterprise imaging software-as-a-service (SaaS) solutions. Four features will be offered when commercially released – edge, storage, vendor neutral archive and data migration.i These cloud solutions, are designed to help enhance healthcare organizations’ efficiency and precision, streamline workflows, and optimize the use of capital and IT resources. The growing volume and complexity of patient cases are putting increasing pressure on hospitals’ IT systems, driving the ne...

 PRESS RELEASE

GE HealthCare names new president and CEO, China

CHICAGO--(BUSINESS WIRE)-- GE HealthCare (Nasdaq: GEHC), a leading global healthcare solutions provider, today announced that Yihao Zhang, president and CEO, China, will retire from the company effective July 1, 2025. Will Song, a Johnson & Johnson veteran for over 20 years, has been named GE HealthCare’s new president and CEO, China, and will join the company on April 1, 2025, ahead of leading the region starting July 1 following Yihao’s departure. Yihao’s planned retirement allowed GE HealthCare to purposefully identify and prepare a qualified successor in Will, an exceptional leader with ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch